Atrix and Block Drug reach settlement on first of legal disputes

Atrix Laboratories, Inc. recently announced that Atrix and Block Drug, a wholly owned subsidiary of GlaxoSmithKline, have settled the first of three licensing disputes submitted last year. The settlement resolves a pricing dispute over Block's sale of Atrix's periodontal product, Atridox and provides payment owed to Atrix for the sale of the product.

David Bethune, Atrix's chairman and chief executive officer, said, "As part of this settlement, we received the payment owed for product sales in 1999. We also implemented a new pricing schedule for future purchases in an effort to resolve issues of this type in the future. While we are pleased to have this dispute behind us, we intend to pursue resolution of the remaining legal issues, including Block's failure to pay Atrix certain milestones following approval by the U.S. Food and Drug Administration (FDA) of Atrisorb-D guided tissue regeneration barrier product."

Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With five unique patented technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products. Atrix has strategic alliances with several pharmaceutical companies including recent collaborations with Pfizer, Elan Corporation, Sanofi-Synthelabo, MediGene and the Novartis company -- Geneva Pharmaceuticals, to use its drug delivery technologies and expertise in the development of new products. Additional information is available on the Atrix Laboratories, Inc. website at www.atrixlabs.com.

Source: Atrix Laboratories, Inc.

Subscribe to our free e-mail newsletter.

Click for a free Buyer's Guide listing.